UCB Pharma

UCB | Inspired by patients. Driven by science..

Launch date

Jan 1928

Employees

Market cap

Enterprise valuation

AUD56.5b (Public information from Sep 2024)

Brussels Brussels-Capital (HQ)

https://twitter.com/ucb_news https://www.facebook.com/ucbbiopharma https://www.linkedin.com/company/ucb-pharma

View job openings

Corporate Venture Fund: UCB Ventures

Revenues, earnings & profits over time

EUR	2020	2021	2022	2023	2024	2025	2026
Revenues	5.3b	5.8b	5.5b	5.3b	5.8b	6.7b	7.4b
% growth	9 %	8 %	(5 %)	(5 %)	10 %	16 %	11 %
EBITDA	1.4b	1.6b	1.3b	1.3b	1.4b	2.1b	2.5b
% EBITDA margin	26 %	27 %	23 %	24 %	24 %	31 %	33 %
Profit	732m	1.1b	418m	343m	418m	882m	1.4b
% profit margin	14 %	18 %	8 %	7 %	7 %	13 %	19 %
EV / revenue	3.3x	3.4x	2.9x	3.3x	5.7x	4.8x	4.1x
EV / EBITDA	12.3x	12.8x	12.6x	13.5x	23.7x	15.5x	12.4x
R&D budget	1.6b	1.6b	1.7b	1.6b	-	-	-
R&D % of revenue	29 %	28 %	30 %	31 %	-	-	-

Source: Dealroom estimates

Date	Investors	Amount	Round
Apr 1999	N/A	N/A	IPO
Jan 2000	N/A	N/A	IPO
Dec 2009	Paul Capital	$100m	Post IPO Equity
May 2022*	Financière de Tubize SA	€94.5m	Post IPO Equity
Total Funding		-

Tech stackLearn more about the technologies and tools that this company uses.

By Country

United States 8 Belgium 2 Switzerland 1 United Kingdom 1

By Industry

By Round

ACQUISITION 5 SERIES C 2 SERIES A 2 SERIES B 1 EARLY VC 1 LATE VC 1

Synosia Therapeutics

ACQUISITION by Biotie Therapies Jan 2011

ACQUISITION by UCB Pharma Jan 2022

exited

Ra Pharmaceuticals

ACQUISITION by UCB Pharma Oct 2019

Beryllium Discovery

ACQUISITION by UCB Pharma Jun 2017

Handl Therapeutics

ACQUISITION by UCB Pharma Nov 2020